{"id":37877,"date":"2025-07-24T15:27:13","date_gmt":"2025-07-24T07:27:13","guid":{"rendered":"https:\/\/flcube.com\/?p=37877"},"modified":"2025-07-24T15:27:14","modified_gmt":"2025-07-24T07:27:14","slug":"sirius-therapeutics-srsd107-receives-ema-approval-for-phase-ii-clinical-trials-in-thromboembolic-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37877","title":{"rendered":"Sirius Therapeutics&#8217; SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases"},"content":{"rendered":"\n<p>China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has received approval from the European Medicines Agency (EMA) to proceed with Phase II clinical trials. SRSD107 is a novel siRNA drug targeting Factor XI (FXI) for the prevention and treatment of thromboembolic diseases.<\/p>\n\n\n\n<p><strong>Mechanism and Advantages<\/strong><br>Factor XI plays a crucial role in pathological thrombosis with minimal impact on normal hemostatic function. SRSD107 selectively inhibits FXI to reduce thrombosis risk while minimizing bleeding adverse events. This approach offers a therapeutic advantage over FXa inhibitors. Potential applications include atrial fibrillation, venous thromboembolism (VTE), cancer-associated thrombosis, end-stage renal disease dialysis patients, and individuals undergoing major orthopedic surgery where bleeding risk limits existing anticoagulant treatments.<\/p>\n\n\n\n<p><strong>Preclinical and Clinical Progress<\/strong><br>Preclinical studies demonstrated that a single subcutaneous injection of SRSD107 can reduce FXI levels to near undetectable levels, with efficacy lasting six months and a favorable safety profile. The drug has completed two Phase I clinical studies in China and Australia, with data presented at the 2024 ASH Annual Meeting and the 2025 ACC Annual Meeting.<\/p>\n\n\n\n<p><strong>Collaboration and Global Strategy<\/strong><br>SRSD107 is co-developed by Sirius Therapeutics and CRISPR Therapeutics. Under their agreement, the parties share development costs and profits, with each responsible for commercialization in China and the U.S. This EU clinical trial approval sets the stage for pivotal studies and global market expansion.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37878,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,69,1962],"class_list":["post-37877","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cvd","tag-sirius-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sirius Therapeutics&#039; SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has received approval from the European Medicines Agency (EMA) to proceed with Phase II clinical trials. SRSD107 is a novel siRNA drug targeting Factor XI (FXI) for the prevention and treatment of thromboembolic diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37877\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirius Therapeutics&#039; SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases\" \/>\n<meta property=\"og:description\" content=\"China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has received approval from the European Medicines Agency (EMA) to proceed with Phase II clinical trials. SRSD107 is a novel siRNA drug targeting Factor XI (FXI) for the prevention and treatment of thromboembolic diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37877\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-24T07:27:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-24T07:27:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2405.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37877#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37877\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sirius Therapeutics&#8217; SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases\",\"datePublished\":\"2025-07-24T07:27:13+00:00\",\"dateModified\":\"2025-07-24T07:27:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37877\"},\"wordCount\":240,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37877#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2405.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CVD\",\"Sirius Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37877#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37877\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37877\",\"name\":\"Sirius Therapeutics' SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37877#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37877#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2405.webp\",\"datePublished\":\"2025-07-24T07:27:13+00:00\",\"dateModified\":\"2025-07-24T07:27:14+00:00\",\"description\":\"China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has received approval from the European Medicines Agency (EMA) to proceed with Phase II clinical trials. SRSD107 is a novel siRNA drug targeting Factor XI (FXI) for the prevention and treatment of thromboembolic diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37877#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37877\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37877#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2405.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2405.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sirius Therapeutics' SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37877#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirius Therapeutics&#8217; SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sirius Therapeutics' SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has received approval from the European Medicines Agency (EMA) to proceed with Phase II clinical trials. SRSD107 is a novel siRNA drug targeting Factor XI (FXI) for the prevention and treatment of thromboembolic diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37877","og_locale":"en_US","og_type":"article","og_title":"Sirius Therapeutics' SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases","og_description":"China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has received approval from the European Medicines Agency (EMA) to proceed with Phase II clinical trials. SRSD107 is a novel siRNA drug targeting Factor XI (FXI) for the prevention and treatment of thromboembolic diseases.","og_url":"https:\/\/flcube.com\/?p=37877","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-24T07:27:13+00:00","article_modified_time":"2025-07-24T07:27:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2405.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37877#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37877"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sirius Therapeutics&#8217; SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases","datePublished":"2025-07-24T07:27:13+00:00","dateModified":"2025-07-24T07:27:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37877"},"wordCount":240,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37877#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2405.webp","keywords":["Clinical trial approval \/ initiation","CVD","Sirius Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37877#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37877","url":"https:\/\/flcube.com\/?p=37877","name":"Sirius Therapeutics' SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37877#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37877#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2405.webp","datePublished":"2025-07-24T07:27:13+00:00","dateModified":"2025-07-24T07:27:14+00:00","description":"China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has received approval from the European Medicines Agency (EMA) to proceed with Phase II clinical trials. SRSD107 is a novel siRNA drug targeting Factor XI (FXI) for the prevention and treatment of thromboembolic diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37877#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37877"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37877#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2405.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2405.webp","width":1080,"height":608,"caption":"Sirius Therapeutics' SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37877#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sirius Therapeutics&#8217; SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2405.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37877"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37877\/revisions"}],"predecessor-version":[{"id":37879,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37877\/revisions\/37879"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37878"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}